Current issues in the clinical management of invasive aspergillosis - the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009

Mycoses

Volumn 54, Issue 5, 2011, Pages

  Ruping M J G T ^a   Vehreschild, J J ^a   Groll, A ^b   Lass Florl C ^c   Ostermann, H ^d   Ruhnke, M ^e   Cornely, O A ^a,f  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antifungal agents; Aspergillus; Diagnosis; Systemic infection

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DRUG EFFICACY; DRUG TREATMENT FAILURE; GERMANY; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; LUNG BIOPSY; NEUTROPENIA; NEUTROPHIL COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUESTIONNAIRE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEB BROWSER;

ANTIFUNGAL AGENTS; ASPERGILLUS; BIOPSY; CHEMOPREVENTION; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DATA COLLECTION; GERMANY; HUMANS; INTERNET; INVASIVE PULMONARY ASPERGILLOSIS; QUESTIONNAIRES; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED;

ASPERGILLUS;

EID: 80052786757     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01989.x     Document Type: Article

References (47)

1. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
2. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
3. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
4. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
5. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
6. Karthaus M, Rüping M, Cornely O et al. Current Issues in the Clinical Management of Invasive Candida Infections - The AGIHO, DMykG, ÖGMM, and PEG Web-based Survey and Expert Consensus Conference 2009. Mycoses 2010; (in press).
7. Alberti C, Bouakline A, Ribaud P et al. Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. J Hosp Infect 2001; 48: 198-206.
8. Oren I, Haddad N, Finkelstein R et al. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66: 257-62.
9. Passweg JR, Rowlings PA, Atkinson KA et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1998; 21: 1231-8.
10. Sherertz RJ, Belani A, Kramer BS et al. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987; 83: 709-18.
11. Qian Y, Willeke K, Grinshpun SA et al. Performance of N95 respirators: filtration efficiency for airborne microbial and inert particles. Am Ind Hyg Assoc J 1998; 59: 128-32.
12. Maschmeyer G, Neuburger S, Fritz L et al. A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol 2009; 20: 1560-4.
13. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
14. Maertens J, Glasmacher A, Selleslag D et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005; 41: e9-14.
15. Lin MT, Lu HC, Chen WL. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 2001; 33: 1621-7.
16. White PL, Linton CJ, Perry MD et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479-86.
17. De Pauw B, Walsh TJ, Donnelly JP et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
18. Klastersky J. Empirical antifungal therapy. Int J Antimicrob Agents 2004; 23: 105-12.
19. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
20. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
21. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
22. Ullmann AJ, Heussel CP, Cornely OA. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002; 346: 1745-7; discussion 7.
23. Marr KA. Empirical antifungal therapy - new options, new tradeoffs. N Engl J Med 2002; 346: 278-80.
24. Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-51.
25. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
26. Hummel M, Rudert S, Hof H et al. Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates. Ann Hematol 2008; 87: 291-7.
27. Rano A, Agusti C, Jimenez P et al. Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures. Thorax 2001; 56: 379-87.
28. Dunagan DP, Baker AM, Hurd DD et al. Bronchoscopic evaluation of pulmonary infiltrates following bone marrow transplantation. Chest 1997; 111: 135-41.
29. White P, Bonacum JT, Miller CB. Utility of fiberoptic bronchoscopy in bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 681-7.
30. Murray PV, O'Brien ME, Padhani AR et al. Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient. Bone Marrow Transplant 2001; 27: 967-71.
31. Hohenadel IA, Kiworr M, Genitsariotis R et al. Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen. Thorax 2001; 56: 115-20.
32. Hohenthal U, Itala M, Salonen J et al. Bronchoalveolar lavage in immunocompromised patients with haematological malignancy - value of new microbiological methods. Eur J Haematol 2005; 74: 203-11.
33. Peikert T, Rana S, Edell ES. Safety, diagnostic yield, and therapeutic implications of flexible bronchoscopy in patients with febrile neutropenia and pulmonary infiltrates. Mayo Clin Proc 2005; 80: 1414-20.
34. Todd T, Enoch DA. Role of bronchoalveolar lavage in evaluating new pulmonary infiltrates on computed tomography in haematology patients with fever unresponsive to broad-spectrum antibiotics. J Med Microbiol 2009; 58: 1660-1.
35. Maschmeyer G, Beinert T, Buchheidt D et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 2009; 45: 2462-72.
36. Lass-Florl C, Resch G, Nachbaur D et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45: e101-4.
37. Carrafiello G, Lagana D, Nosari AM et al. Utility of computed tomography (CT) and of fine needle aspiration biopsy (FNAB) in early diagnosis of fungal pulmonary infections. Study of infections from filamentous fungi in haematologically immunodeficient patients. Radiol Med 2006; 111: 33-41.
38. Rickerts V, Mousset S, Lambrecht E et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007; 44: 1078-83.
39. Maschmeyer G, Haas A. Defining clinical failure for salvage studies. Med Mycol 2006; 44: 315-8.
40. Bohme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
41. Boutboul F, Alberti C, Leblanc T et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34: 939-43.
42. Woods G, Miceli MH, Grazziutti ML et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110: 830-4.
43. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
44. Edwards JE Jr, Bodey GP, Bowden RA et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997; 25: 43-59.
45. Guery BP, Arendrup MC, Auzinger G et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35: 55-62.
46. Guery BP, Arendrup MC, Auzinger G et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment. Intensive Care Med 2009; 35: 206-14.
47. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.